Home Blog Page 1725

MIXUE Snow King is Soaring in the Sky! Two MIXUE Snow King-themed painted airplanes Take Flight for the First Time, Spreading Happiness above the Clouds!

SINGAPORE, Oct. 28, 2025 /PRNewswire/ — On October 28, two MIXUE Snow King-themed painted airplanes completed their maiden flights successfully. During the flight, Snow King invited our fans to join the journey, offering them a first taste of this joyful adventure. From now on, passengers will have the chance to enjoy a jubilant trip with Snow King!

MIXUE Snow King-themed painted airplane
MIXUE Snow King-themed painted airplane

The two specially designed airplanes, jointly introduced by Hainan Airlines and MIXUE, feature Snow King as the main figure—flying joyfully across the blue skies and fluffy clouds, holding an ice cream scepter in hand and a vibrant red cape.

MIXUE Snow King-themed painted airplane first flight event
MIXUE Snow King-themed painted airplane first flight event

Inside the cabin, Snow King is everywhere—from the overhead bin, the headrest covers to the tray tables that showcase Snow King and MIXUE’s classic products. MIXUE has created a fully immersive and delightful travel experience for all passengers.

Snow King Shows the Fans around MIXUE’s Super Factory in Hainan
Snow King Shows the Fans around MIXUE’s Super Factory in Hainan

During the customization of the aircraft, Snow King live-streamed the entire painting and assembling process, inviting all fans online to witness the creation of the aircraft. This hospitality doesn’t just stop here. Snow King also treated the fans to an exclusive visit to MIXUE’s super factory in Hainan. There, they explored every process of coffee making, from raw bean storage, roasting to packaging. Fans gained a deeper understanding of how MIXUE delivers high-quality, affordable, and authentic beverages. They expressed that the firsthand visit deepened their fondness of MIXUE and Snow King!

“I love you, You love me, MIXUE ice cream&tea”—this is more than just a slogan of the brand. This catchy phrase reflects MIXUE’s commitment to creating sweet and delightful moments through innovative spaces and occasions. On social media, netizens have been buzzing with excitement about the “Snow King” themed painted aircraft, leaving enthusiastic comments like:

-“Snow King is really leveling up! I’m going to pick this flight next time!”

-“Snow King can fly now!”

-“Snow King, what other surprises do you have in store for us?”

MIXUE Snow King-themed painted airplane
MIXUE Snow King-themed painted airplane

In the future, passengers aboard MIXUE’s Snow King-themed airplane will not only be able to enjoy MIXUE’s beverages on the ground but also be surrounded by Snow King’s adorable image above the clouds. Each journey will promise them a memorable, sweet adventure, spreading joy to every corner of the trip.

IFS Delivers 22% ARR Growth as Industrial AI moves from Promise to Performance

Global enterprises scale IFS’s Industrial AI across mission-critical operations, driving larger deal sizes and accelerating expansion

LONDON, Oct. 28, 2025 /PRNewswire/ — IFS, the leading provider of Industrial AI software, today announced its FY2025 Year-to-Date (YTD) financial results, demonstrating sustained profitable growth, as the world’s largest industrial enterprises move from AI experimentation to deployment across their most critical operations.

Q3 FY2025 YTD Financial Highlights

  • Annual Recurring Revenue (ARR): +22% YoY
  • Cloud Revenue: +31% YoY
  • Recurring Revenue: +20% YoY, now representing 82% of total revenue

Unlike many AI projects that are yet to achieve real impact, IFS.ai is delivering meaningful and measurable outcomes for customers. This is why many of the world’s largest industrial companies are choosing IFS.ai, including: Arcelor Mittal, Boralex, Callaway, Collins Aerospace, Dixstone, Hitachi Energy, Japan Airlines, OFI, TotalEnergies and Westinghouse. These customers are increasing their investments in IFS, driving growth in recurring revenue, deal sizes and customer expansion.

Why Enterprise Leaders Are Choosing IFS: Industrial AI Delivering in the Real World

IFS’s Industrial AI capabilities are purpose-built for the operational complexity of industries that manufacture goods, maintain critical assets, and manage service-intensive operations. This domain expertise, combined with cutting-edge AI innovation, enables IFS to deliver outcomes that traditional vendors cannot match.

  • IFS.ai, embedded across IFS solutions, delivers industry-specific intelligence that orchestrates operational complexity, optimizes real-time decision-making, and transforms efficiency at scale; contextual insights that generic AI simply cannot provide.
  • Nexus Black, IFS’s AI innovation accelerator, is already delivering breakthrough AI products and measurable customer results within weeks. Forward-deployed engineers turn customer challenges into AI solutions. IFS is differentiated as these AI solutions are productised at unprecedented speed and scale.
  • IFS Loops agentic Digital Workers autonomously manage complex workflows that previously required extensive manual intervention, operating seamlessly across any enterprise data source, be it IFS or any other vendor. Early deployments are demonstrating significant efficiency gains and faster decision-making.
  • IFS’s Q3 acquisition of 7Bridges adds advanced AI-driven supply chain, logistics, and transportation optimization capabilities, further extending IFS’s Industrial AI leadership.  

Mark Moffat, CEO of IFS, commented: “Our 22% ARR growth and increase in average deal size is driven by our AI investments and reflects a clear market shift: the world’s largest industrial enterprises are done experimenting with AI: they’re deploying it at scale, and they’re choosing IFS to co-innovate with them.

“They’re choosing us because Industrial AI purpose-built for their operations delivers outcomes they can measure and scale. That’s only possible because of our deep industry expertise that has enabled IFS to stand out in asset and service management. That proven value drives expansion. As they see returns, they invest more, and that dynamic is accelerating.”

Matthias Heiden, CFO of IFS, said: “These results demonstrate disciplined execution. Our recurring revenue base at 82% of total revenue provides strong visibility and funds continued innovation. As customers realize measurable returns, they’re making larger commitments and expanding faster, strengthening both our business model and competitive position.”

Momentum Accelerating Into 2026

IFS’s ability to create customer impact continues expanding through strategic partnerships and relentless innovation. The company’s thriving global partner ecosystem played a crucial role in enabling continued scaling and deal size growth throughout FY2025 YTD.

On November 13 in New York, IFS will host Industrial X Unleashed, uniting AI leaders including Anthropic, Boston Dynamics, Microsoft, PwC, and Siemens to showcase breakthrough Industrial AI applications. The event will feature live demonstrations of how AI, large language models, robotics, and enterprise software are transforming operations across the world’s most critical industries.

Highlights

  • Appointed Kriti Sharma as CEO of Nexus Black to lead next generation AI innovation
  • Acquired 7Bridges to transform supply chains with Industrial AI
  • Established partnership with Climatiq to integrate real-time sustainability data into IFS Cloud
  • Acquired TheLoops: first agentic AI workforce for mission-critical industries
  • Named Customers’ Choice in the 2025 Gartner Peer Insights Voice of the Customer for Cloud ERP

IFS Press Contacts:

EUROPE / MEA / APJ: Adam Gillbe
IFS, Director of Corporate & Executive Communications
Email: adam.gillbe@ifs.com

NORTH AMERICA / LATAM: Mairi Morgan
IFS, Director of Corporate & Executive Communications
Email: mairi.morgan@ifs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ifs/r/ifs-delivers-22–arr-growth-as-industrial-ai-moves-from-promise-to-performance,c4257681

Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE

News Summary:

  • The announcement represents a significant step towards advancing secure AI infrastructure across UAE, aligned with the US-UAE AI Acceleration Partnership.
  • Cisco will power, connect, and secure a large-scale AI cluster deployed by G42, featuring AMD’s advanced MI350X GPUs.
  • The collaboration further embeds trusted US technology partners into G42’s AI infrastructure roadmap.

SAN JOSE, Calif., and ABU DHABI, UAE, Oct. 28, 2025 /PRNewswire/ — Cisco (NASDAQ: CSCO), the worldwide leader in networking and security, and G42, the UAE-based global leader in artificial intelligence, today announced a major expansion of their collaboration to advance secure AI infrastructure. This initiative is further evidence of Cisco’s long-term commitment to driving digital advances across the region, building secure, trusted and high-performance infrastructure for the AI era.

Chuck Robbins, Chair & CEO of Cisco and Peng Xiao, Group CEO of G42 in Abu Dhabi today
Chuck Robbins, Chair & CEO of Cisco and Peng Xiao, Group CEO of G42 in Abu Dhabi today

 

A Trusted Foundation for the UAE’s AI Economy

Cisco will power, connect, and secure a large-scale AI cluster deployed by G42, featuring AMD’s advanced MI350X GPUs. This deployment integrates Cisco’s full-stack, secure AI infrastructure, including compute, networking, security, storage, optics, as well as observability and analytics tools, delivering scalable performance and unified management for the region’s most advanced AI workloads.

Cisco will also act as the technology integrator within G42’s Regulated Technology Environment (RTE), a gold-standard compliance and security framework designed to ensure that advanced compute infrastructure operates with the highest levels of protection, transparency, and governance, preventing unauthorized access, transfer, or misuse of advanced compute systems.

The collaboration builds on joint efforts under the broader US–UAE AI Acceleration Partnership, a key program advancing bilateral technology goals, whose flagship projects include the 1GW Stargate UAE cluster undergoing construction in Abu Dhabi and the 5GW UAE-US AI technology campus that was announced during President Trump’s state visit to the UAE in May 2025.

Peng Xiao, Group CEO of G42, said: “This collaboration with Cisco represents the next phase of deepening trust and technological alignment between the US and UAE under the AI Acceleration Partnership. It reinforces our shared commitment to building high-performance, secure, sovereign and compliant AI infrastructure that enables global innovation while upholding the highest standards of governance.”

Chuck Robbins, Chair and CEO of Cisco, said: “Cisco is proud to deepen our partnership with G42, powering the UAE’s next wave of AI innovation by delivering secure, trusted, high-performance infrastructure. This collaboration strengthens the US-UAE AI Acceleration Partnership and underscores Cisco’s role in the UAE’s digital transformation journey. Together, we are building the foundation for a future driven by responsible and impactful innovation.”

Dr. Lisa Su, Chair and CEO, AMD, said: “AMD is proud to partner with Cisco and G42 to power the next generation of AI infrastructure in the UAE. Our AMD Instinct MI350X accelerators deliver the performance, efficiency, and scalability needed to advance secure, sovereign AI innovation. This initiative strengthens the UAE’s position as a global leader in innovative AI development and demonstrates how technology initiatives like the US-UAE AI Acceleration Partnership can drive national digital ambitions.” 

Driving the Region’s Digital Momentum

According to Cisco’s latest AI research, 92% of organizations in the UAE plan to deploy AI agents, and 41% expect them to work alongside employees within a year. Yet only 25% have robust GPU capacity. It is a gap that this partnership aims to close by delivering scalable, secure AI infrastructure built for growth.

With AI rapidly becoming the main driver of innovation, Cisco’s engagement in digital transformation across the UAE has never been more vital. This collaboration represents another bold step in Cisco’s strategy – turning innovation into impact and accelerating the region’s digital future.

Cisco’s Secure, End-to-End AI Infrastructure

Cisco uniquely delivers an end-to-end AI-ready data center solution, combining compute, networking, security, automation and optics.  The deployment will leverage Cisco’s end-to-end AI-ready data center portfolio, featuring Cisco UCS 885A servers equipped with AMD MI350X GPUs for compute, high-speed Nexus 9K 800G switches for networking, the VAST AI Operating System hosted on UCS servers, Firepower 4200 next-generation firewalls for security, Nexus Dashboard and Intersight for network automation and compute management. In addition, it will feature the latest Cisco optics to enable the highest performing and most reliable networks, and Cisco Advanced Services for planning, design, and implementation.

The collaboration further strengthens G42’s network of trusted US technology partners contributing to the Regulated Technology Environment (RTE) framework, reinforcing a model grounded in transparency and accountability.

G42 and Cisco will work in close coordination with relevant U.S. government agencies to obtain the necessary licenses and regulatory clearances for deployment, which is expected to advance in the coming months pending final approvals.

About Cisco 

Cisco (NASDAQ: CSCO) is the worldwide technology leader that is revolutionizing the way organizations connect and protect in the AI era. For more than 40 years, Cisco has securely connected the world. With its industry leading AI-powered solutions and services, Cisco enables its customers, partners and communities to unlock innovation, enhance productivity and strengthen digital resilience.  With purpose at its core, Cisco remains committed to creating a more connected and inclusive future for all. Discover more on The Newsroom and follow us on X at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco’s trademarks can be found at http://www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word ‘partner’ does not imply a partnership relationship between Cisco and any other company.

About G42

G42 is a technology holding group and a global leader in creating visionary artificial intelligence for a better tomorrow. Born in Abu Dhabi and operating worldwide, G42 champions AI as a powerful force for good across industries. From molecular biology to space exploration and everything in between, G42 realizes exponential possibilities today. To know more, visit www.g42.ai

 

SI GROUP OPENS NEW INNOVATION CENTER

State-of-the-art facility expands company’s global research and development capabilities

THE WOODLANDS, Texas, Oct. 28, 2025 /PRNewswire/ — SI Group, a leading global developer and manufacturer of performance additives, process solutions, and chemical intermediates, announced the official opening of its European Innovation Centre (EIC) in Four Ashes, United Kingdom. This milestone marks an important expansion of SI Group’s global innovation network, strengthening R&D and application development to better serve customers worldwide.

The new state-of-the-art facility is equipped with advanced tools and resources to support a wide range of research activities. With a focus on plastics and rubber application development, as well as analytical characterization, the EIC will serve as a collaborative hub for addressing technical challenges and driving sustainable innovation in partnership with customers and industry leaders.

In addition to the new Four Ashes, UK facility, SI Group also operates Innovation Centers in:

  • Houston, Texas, USA
  • Rotterdam Junction, New York, USA
  • Morgantown, West Virginia, USA
  • Lote, India
  • Shanghai, China

“The opening of the European Innovation Centre represents a significant investment in SI Group’s global innovation capabilities,” said Robert Kaiser, VP Strategic Marketing and Managing Director – EMEA at SI Group. “Together with our five additional Innovation Centers, we’re building a robust, globally connected R&D network that enhances competitiveness, delivers advanced solutions tailored to regional needs, and supports the long-term growth of our business.”

The inaugural event was held on October 23, 2025, featuring a tour of the facility and a keynote address by His Majesty’s Lord-Lieutenant of Staffordshire, Professor Elizabeth Barnes CBE, on behalf of His Majesty King Charles III. Media representatives and industry professionals were invited to attend.

About SI Group
SI Group is a global leader in the innovative technology of performance additives, process solutions, active pharmaceutical ingredients, and chemical intermediates. SI Group solutions are essential to enhancing the quality and performance of countless industrial and consumer goods within plastics, rubber & adhesives, fuels & lubricants, oilfield, and pharmaceutical industries. SI Group’s global manufacturing footprint includes 19 facilities on three continents, serving customers in 80 countries with approximately 1,600 employees worldwide. In 2025, SI Group received a bronze award for corporate social responsibility by EcoVadis and is ranked among the top 35 percent of the more than 150,000 companies worldwide. SI Group innovates and drives change to create value with a passion for safety, chemistry, sustainability, and extraordinary results. Learn more at www.siigroup.com.

Media Contact:
Joseph Grande
ph: + 1.413.684.2463
joe@jgrandecommunications.com

Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses

HONG KONG, Oct. 28, 2025 /PRNewswire/ — Sisram Medical Ltd (the “Company” or “Sisram“, 1696.HK; together with its subsidiaries collectively referred to as the “Group“), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets.

In the third quarter of 2025, the Company achieved double-digit revenue growth compared to the same period last year, driven by strong double-digit year-on-year growth in new orders, primarily supported by robust demand across key markets in China, South Korea, and Thailand.

The EBD business maintained strong growth, with sustained market momentum for Alma Harmony, the award-winning multiplatform launched globally in March 2025, which recorded a significant volume of new orders during the quarter. Building on this success, the Soprano family of laser devices delivered impressive performance in the APAC region, highlighted by the latest launch of Soprano in China that secured substantial new orders.

The injectables business continued its strategic expansion, serving as a key growth engine for Sisram. Notably, DAXXIFY received approval from the National Medical Products Administration, becoming the first botulinum toxin type A product approved in Mainland China that features a proprietary Peptide Exchange Technology (PXT) and a stabilized-peptide formulation. With dedicated efforts to accelerate commercial preparations, the launch of DAXXIFY in Mainland China remains on track, injecting renewed momentum into the Company’s injectables segment and overall ecosystem.

Globally, Sisram deepened its footprint in strategic markets, advancing its “glocalization” strategy through a series of focused initiatives. The newly established direct sales office in Thailand continued to deliver strong injectable sales, demonstrating effective localization. In the U.S., the Company officially launched Universkin by Alma, the world’s first AI-assisted skincare products, in July 2025, following a successful pilot. Additionally, the Alma IQ, Alma’s intelligent skin analysis platform continued its global expansion, enabling practitioners to offer holistic, intelligent medical aesthetic solutions that enhance clinical outcomes and elevate patient experiences.

Mr. Lior Dayan, CEO of Sisram and Alma, said: “Our strong third-quarter results underscore the effective execution of our growth strategy. With the EBD segment delivering consistent performance and the injectables portfolio entering its next phase of expansion, we are advancing balanced growth engines built for scale and long-term value creation. Today, we are proud to lead the next generation of intelligent aesthetic solutions that significantly enhance partner value and elevate patient experiences. With our diversified portfolio and strong market momentum, we are well positioned to capture new opportunities and further strengthen our leadership as a global provider of advanced, holistic medical aesthetic solutions.”

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK) is a global leader in medical aesthetic solutions with over 25 years of expertise in Energy-Based Devices (EBD). Built on a legacy of innovation and clinical excellence, the Company’s synergistic ecosystem spans EBD technologies, injectables, diagnostics, and complementary solutions. Serving customers in over 110 countries and regions, Sisram delivers award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram has been listed on the Main Board of the Hong Kong Stock Exchange since September 2017.

For more information, please visit: https://sisram-medical.com/.

 

MOVUS wins the Mining Beacon Breakthrough Innovation Award at IMARC 2025 for its breakthrough in prescriptive AI for mining operations

SYDNEY, Oct. 28, 2025 /PRNewswire/ — MOVUS (now part of Infinite Uptime Inc.), an Australian pioneer in industrial asset intelligence, has been honored with the Mining Beacon Breakthrough Innovation Award at the International Mining and Resources Conference (IMARC) 2025. The award recognizes MOVUS’s contribution to transforming asset maintenance for the mining industry through its breakthrough innovation in intelligent industrial monitoring, which works seamlessly with its cloud-powered prescriptive AI platform, PlantOS™

Sanjeev Kumar, Business Unit Head – ANZ, Infinite Uptime, receiving the Mining Beacon Breakthrough Innovation Award from Rob Adamson, Executive Chairman, RFC Ambrian Limited, at IMARC 2025 in Sydney.
Sanjeev Kumar, Business Unit Head – ANZ, Infinite Uptime, receiving the Mining Beacon Breakthrough Innovation Award from Rob Adamson, Executive Chairman, RFC Ambrian Limited, at IMARC 2025 in Sydney.

Held in Sydney, Australia, from October 21–23, 2025, IMARC is among the world’s most influential gatherings for the mining and resources industry. The event brought together over 10,000 delegates from 120+ countries, including government leaders, mining majors, investors, and technology innovators, with a shared focus on sustainability, innovation, and operational excellence

MOVUS made a strong impact with live demonstrations of its PlantOS™ platform, attracting operators eager to explore smarter, AI-assisted decision-making to optimize reliability, productivity, and efficiency.

The Mining Beacon Breakthrough Innovation Award recognized MOVUS for its breakthrough innovation that combines advanced hardware with an AI-powered analytics engine. At its core is Ultra vSense, the world’s first piezoelectric sensor to integrate vibration, temperature, and RPM measurement in a single compact and rugged device built for mining’s toughest conditions. Ultra vSense transmits real-time data to PlantOS™, the Industrial Prescriptive AI platform, enabling fault diagnostics and prescriptive recommendations.

The jury noted, “MOVUS’ innovation addresses some of the key challenges facing the sector, replacing multiple sensors across sites and helping clients cut their costs by up to 40% while driving new levels of safety, efficiency, and reliability in mining.” 

Karthikeyan Natarajan, Co-CEO of Infinite Uptime Inc., said, “The Mining Beacon Breakthrough Innovation Award celebrates more than a product; it recognizes a mindset of an industry in transformation. At Infinite Uptime, we’re reimagining how complex industrial operations are run by combining data, AI, and deep domain expertise to predict and prevent failures before they happen and reduce the cost of production. This recognition reaffirms our mission to make reliability a science — helping the world’s leading manufacturers build smarter, safer, and more sustainable operations.” 

Malcolm Schulstad, COO of MOVUS, added, “IMARC was a great week for MOVUS. We had a lot of interest from mining companies and partners keen to modernize their maintenance practices with PlantOS, and taking home the Innovation Award shows how an Australian company can deliver technology that helps the industry boost reliability, cut costs, and make operations safer. It’s a privilege to be part of the mining community.”

About MOVUS: 

MOVUS (now part of Infinite Uptime Inc.) is an Australian technology innovator that extends the life of industrial assets, reduces unplanned downtime, and supports more sustainable operations through smart, scalable monitoring solutions. Powered by PlantOS™, the world’s most user-validated prescriptive AI platform, MOVUS combines AI-powered insights, continuous diagnostics, and hands-on support to help industries move from predictive to prescriptive maintenance with ease and precision. 

https://movus.com.au/

 

The MOVUS team, along with the Infinite Uptime leadership team at IMARC 2025, Sydney.
The MOVUS team, along with the Infinite Uptime leadership team at IMARC 2025, Sydney.

 

 

Fosun Pharma Announces 2025Q3 Financial Results

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025

SHANGHAI, Oct. 28, 2025 /PRNewswire/ — On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025. In the first three quarters of 2025, Fosun Pharma achieved operating revenue of RMB29,393 million, net profit attributable to shareholders of RMB2,523 million. The revenue from Innovative Drugs grew steadily, exceeding RMB6,700 million in the first three quarters of 2025, up by 18.09% period-on-period, implying a continued optimization of revenue structure. Fosun Pharma

Meanwhile, Fosun Pharma continued to deepen lean operations, drive cost reduction and efficiency enhancement, and advance asset-light strategies to optimize assets and financial structure, actively strengthen supply chain management and operational efficiency, and achieve healthy operating cash flow. In the first three quarters of 2025, the net cash flow from operating activities of Fosun Pharma amounted to RMB3,382 million, up by 13.23% period-on-period, representing a sustained improvement in operational quality.

Revenue from Innovative Products Maintains Steady Growth

Fosun Pharma’s innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors, and immune-inflammatory disorders, while emphasizing core technology platforms including antibodies/ADCs, cell therapy, and small molecules, building a synergistic, open, and global innovative R&D system.

In the third quarter of 2025, several self-developed Innovative Drugs from Fosun Pharma achieved key milestones in major markets. Notably, 1 additional indication for the innovative small molecule CDK4/6 inhibitor Fovinaciclib Citrate Capsules (Chinese trade name:复妥宁®), of which Fosun Pharma owns independent intellectual property rights, was approved in Chinese Mainland. The inhibitor is for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, bringing more diverse treatment options to breast cancer patients in China.

In September 2025, the self-developed denosumab injection (project no.: HLX14), in both 60 mg/mL and 120 mg/1.7 mL presentations, was approved for launch successively in the United States and the European Union, becoming the first domestically developed denosumab to be approved overseas, covering all original indications. This provides additional therapeutic options in multiple areas related to bone loss, including osteoporosis.

In the hematology tumors field, the drug registration application of Brexucabtagene Autoleucel Injection (project code: FKC889) of Fosun Kairos was accepted by the National Medical Products Administration (NMPA) in September 2025. The declared indication for this application is for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Strengthening Original Innovation Capability, Building a High-Value Pipeline Portfolio

Fosun Pharma committed to innovation-driven sustainable growth, emphasizing the rational allocation of R&D resources and efficiency enhancement. The Group has gradually built a high-value pipeline portfolio and deployed radiopharmaceuticals, RNA, gene therapy, AI drug R&D and other cutting-edge technologies in order to facilitate the R&D process. Meanwhile, Fosun Pharma continuously strengthens its fundamental innovation capabilities and advances the deep integration of scientific and industrial innovation.

In terms of R&D investment, in the first three quarters of 2025, Fosun Pharma’s R&D investment amounted to  RMB3,998 million in total, up by 2.12% period-on-period. In particular, R&D expenses amounted to RMB2,730 million. In the third quarter of 2025, R&D expenses amounted to RMB1,013 million, up by 28.81% period-on-period. The investment primarily focused on cutting-edge technology platforms such as radiopharmaceuticals and cell therapy, as well as global multicenter clinical trials of high-value pipelines, including HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) and HLX43 (PD-L1-targeted antibody-drug conjugate).

Fosun Pharma’s self-developed innovative anti-PD-1 monoclonal antibody (mAb) Han Si Zhuang (serplulimab injection) is making steady progress across multiple clinical studies. Among them, the phase 3 clinical study of Han Si Zhuang in combination with chemotherapy for the neo-/adjuvant treatment of gastric cancer has met the primary endpoint, supporting an early new drug application submission. Han Si Zhuang has become the world’s first perioperative (pre-/post-surgical) treatment regimen for gastric cancer in which an immunotherapy monotherapy replaces postoperative adjuvant chemotherapy, marking a major breakthrough in this field. In October, the U.S. bridging study of serplulimab injection in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) has completed enrollment of all 200 patients, laying a solid foundation for the subsequent submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). As the world’s first anti-PD-1 mAb approved for 1L treatment of ES-SCLC, serplulimab has been approved in nearly 40 countries and regions including China, the U.K., Germany, Singapore and India, serving as a high-quality example of Chinese innovation drugs reaching global markets.

In October 2025, HLX43 (PD-L1-targetede antibody-drug conjugate) for injection was granted Orphan-Drug Designation (ODD) by the U.S. FDA for the treatment of thymic epithelial tumors (TETs). This designation will facilitate the subsequent R&D, registration, and commercialization of the product for the relevant indication in the United States. HLX43 is a potential best-in-class (BIC) broad-spectrum anti-tumor antibody-drug conjugate (ADC) that combines dual mechanisms of action—immune checkpoint blockade and payload-mediated cytotoxicity. As the world’s first PD-L1 ADC developed for TETs, HLX43 has demonstrated promising preliminary efficacy in the later-line treatment of patients with TC. It is positioned to address the unmet clinical need for ADC therapies in this rare and highly aggressive malignancy. Currently, Fosun Pharma’s subsidiary, Henlius, is advancing the clinical development of HLX43 at full speed, with over 400 patients enrolled globally.

In September 2025, Fosun Pharma established a radiotherapy business platform, Xingrui Jingxuan, which will deploy diagnosis-therapy integrated radiopharmaceuticals development in pan-tumor through both independent R&D and collaborative pathways, bringing more benefits to patients.

Launching Share Incentive Scheme, Successfully Issuing First Medium-to-Long Term Sci-Tech Innovation Bond in Private Pharmaceutical Industry

In addition, in the first three quarters of 2025, Fosun Pharma completed its A-share and H-share repurchase plans on schedule and proposed adoption of the 2025 A share option incentive scheme and the H share restricted share unit (RSU) scheme, further strengthening its long-term incentive mechanism. In August 2025, the Group successfully issued RMB 1 billion of medium-to-long-term Sci-Tech Innovation Bonds with a maturity of two years, becoming the first private pharmaceutical company to issue such bonds after the joint announcement of the People’s Bank of China and the China Securities Regulatory Commission in May 2025 regarding support for Sci-Tech Innovation Bonds. The bonds carry a coupon rate of 2.70% and will provide strong funding support for Fosun Pharma as it deploys in key scientific innovation areas, accelerating the transformation and commercialization of innovative products.

Looking forward, Fosun Pharma will continue to adhere to innovation-driven development, optimize R&D resource allocation, accelerate the clinical progress and commercialization of high-potential pipeline, and remain committed to delivering higher-quality and more accessible healthcare products and services to patients worldwide.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy – Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence, and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.

  

Natura Bissé becomes the first and exclusive ‘OFFICIAL SPA BRAND’ OF The World’s 50 Best Hotels 2025

BARCELONA, Spain, Oct. 28, 2025 /PRNewswire/ — The Spanish skincare brand takes a key step in its commitment to remaining a global leader in the world of high-end wellness experiences and becomes the first and exclusive “Official Spa Brand” of The World’s 50 Best Hotels, the global authority in hospitality excellence. With this partnership, Natura Bissé strengthens its commitment to luxury hotels as part of its international growth strategy.

Natura Bissé First and Exclusive Official Spa Brand of The World's 50 Best Hotels.
Natura Bissé First and Exclusive Official Spa Brand of The World’s 50 Best Hotels.

The World’s 50 Best Hotels awards ceremony will be held in London this week, bringing together the world’s top hoteliers for a three-day event. For the occasion, Natura Bissé will curate a series of innovative experiences designed to inspire attendees in their continuous pursuit of excellence for their guests and to support a sustainable and profitable business model.

This is a key alliance at a time of unprecedented growth in luxury tourism. Demand for high-end, innovative experiences continues to rise, and wellness is becoming a core element of the new emotional and transformative luxury. The latest report from the Global Wellness Institute* states that the wellness sector has grown by 9% annually since 2020 and is projected to reach $9 trillion by 2028 – nearly double its size in 2019.

* Global Wellness Institute (2024). The Global Wellness Economy Reaches a New Peak of $6.3 Trillion And Is Forecast to Hit $9 Trillion by 2028. Link to the article.

“Natura Bissé was born as a spa brand, and for over four decades we have collaborated with some of the world’s most iconic hotels. It is an honor to become the first and exclusive official spa partner of The World’s 50 Best Hotels. We are convinced we can bring real value to an industry we strongly believe in—one that will play a key role in a new global paradigm that increasingly demands truly transformative wellness experiences.”, Lluis Uriach, Strategic Projects Director of Natura Bissé Group.

Natura Bissé is currently present in over 450 hotels around the world, including major groups such as The Ritz-Carlton, Four Seasons, Waldorf Astoria, Rosewood, Belmond, St. Regis, Fairmont, Mandarin Oriental and Grand Hyatt. The brand’s treatments make a true difference in the spa, its 100% charitable amenities—recently awarded by Condé Nast Traveler Spain— delight guests in their rooms, and a carefully curated retail selection allows them to continue their self-care at home.

“We are thrilled to partner with Natura Bissé, a leading name in skincare and spa, that shares our unwavering pursuit of excellence and unforgettable experiences. We are confident they will bring great added value to the 50 Best community and the properties on The World’s 50 Best Hotels list.”, Craig Hawtin-Butcher, 50 Best Managing Director.

Contact:

Mireia Gallart, mireiagallart@naturabisse.com + 34 93 591 0231